Technical Analysis for NTLA - Intellia Therapeutics, Inc.

Grade Last Price % Change Price Change
D 29.02 -2.55% -0.76
NTLA closed down 2.55 percent on Friday, December 8, 2023, on approximately normal volume.
7 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Multiple of Ten Bearish Other 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
NR7 Range Contraction -2.55%
NR7-2 Range Contraction -2.55%
Wide Bands Range Expansion -2.55%
Down 3 Days in a Row Weakness -2.55%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Intellia Therapeutics, Inc. Description

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Immune System Emerging Technologies Molecular Biology Genetics Hepatitis B Precision Medicine Metabolism Liver Disease Chimeric Antigen Receptor T Cell Amyloid Amyloidosis Chimeric Antigen Receptor Hematopoietic Stem Cell Hepatitis B Virus CRISPR Antitrypsin Deficiency Cell Product Genome Editing Inborn Errors Of Metabolism Cas9 Transthyretin Transthyretin Amyloidosis

Is NTLA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 47.475
52 Week Low 22.665
Average Volume 1,396,910
200-Day Moving Average 36.76
50-Day Moving Average 28.26
20-Day Moving Average 28.87
10-Day Moving Average 30.23
Average True Range 1.78
RSI (14) 49.49
ADX 21.49
+DI 28.64
-DI 23.06
Chandelier Exit (Long, 3 ATRs) 27.04
Chandelier Exit (Short, 3 ATRs) 28.02
Upper Bollinger Bands 33.32
Lower Bollinger Band 24.42
Percent B (%b) 0.52
BandWidth 30.82
MACD Line 0.54
MACD Signal Line 0.54
MACD Histogram 0.0032
Fundamentals Value
Market Cap 1.71 Billion
Num Shares 59.1 Million
EPS -2.00
Price-to-Earnings (P/E) Ratio -14.48
Price-to-Sales 36.49
Price-to-Book 7.69
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.59
Resistance 3 (R3) 31.81 31.19 31.16
Resistance 2 (R2) 31.19 30.53 31.07 31.01
Resistance 1 (R1) 30.10 30.13 29.79 29.88 30.87
Pivot Point 29.48 29.48 29.32 29.36 29.48
Support 1 (S1) 28.39 28.82 28.08 28.17 27.17
Support 2 (S2) 27.77 28.42 27.65 27.03
Support 3 (S3) 26.68 27.77 26.88
Support 4 (S4) 26.46